FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to gerontology, geriarthria, clinical laboratory diagnostics, and can be used to assess the degree of accumulation of senescent cells in patients over 65 years old. Performing: a) sampling peripheral venous blood, b) extraction of mononuclear cell and plasma fractions from peripheral blood, c) determining in a sample of a fraction of mononuclear cells of blood, the number of cells positive for marker CD34, in percentage (CD34+%), d) determination of VCAM content in blood plasma in ng/ ml, e) calculation of a coefficient reflecting the degree of accumulation of senescent cells in the body by formula: CSC=(Patient age -65)*(-0.14)+(CD34+%-0.04)*(-2.27)+(2*VCAM-22.95)*(-0.02) +(VCAM∧4-277415.52)*(2.15*10∧(-7))+6.27, f) determining the degree of accumulation of senescent cells in patients over 65 years old. If the CSC value is less than 4, the patient is referred to a group with a low degree of accumulation of senescent cells in tissues. If the CSC value is higher than or equal to 4, the patient is referred to a group with a high degree of accumulation of senescent cells. Extraction of mononuclear cell and plasma fractions from peripheral blood can be performed in density gradient on ficoll. Flow cytometry can be used to estimate the CD34+ cell content. To assess the level of VCAM, enzyme immunoassay can be used.
EFFECT: method enables to classify a patient as a high or low degree of accumulation of senescent cells, which is necessary for making a clinical decision on further management of the patient or assessing the effectiveness of geroprotective, including senolytic therapy, by calculating the degree of accumulation of senescent cells by indirect indicators obtained during clinical and laboratory studies without taking tissue biopsy materials and using a formula developed on the basis of multiparameter analysis of relationships of various biomarkers of senescent cells at systemic, tissue and cellular levels.
4 cl, 2 dwg, 3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR DESTROYING AGING CELLS AND FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH AGING | 2015 |
|
RU2716256C2 |
TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
TRANSIENT CELLULAR REPROGRAMMING TO REVERSE CELL AGING | 2019 |
|
RU2801316C2 |
METHOD FOR DIAGNOSING OR DETERMINING THE RISK OF DEVELOPING COGNITIVE IMPAIRMENT | 2023 |
|
RU2821890C1 |
METHOD OF ASSESSING AGE-RELATED CHANGES OF HUMAN CARDIOVASCULAR SYSTEM | 2012 |
|
RU2485886C1 |
DIAGNOSTIC ANTIBODIES TO ADVANCED GLYCATION END PRODUCTS | 2018 |
|
RU2788905C2 |
METHOD FOR CULTURING FIBROBLASTS FOR SUBSTITUTION THERAPY | 2006 |
|
RU2320720C2 |
COMPOSITIONS AND METHODS OF TREATING, PREVENTING AND REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | 2020 |
|
RU2812903C2 |
METHOD FOR DIFFERENTIAL LIFETIME DIAGNOSIS OF ALZHEIMER'S DISEASE | 2023 |
|
RU2821893C1 |
METHOD FOR PREDICTION OF EFFECTIVENESS OF CONSERVATIVE TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2023 |
|
RU2817324C1 |
Authors
Dates
2024-12-04—Published
2023-10-24—Filed